Cell Engineering Division -CELL BANK-

1) Efforts of RIKEN BRC promoting COVID-19 related research

RIKEN BioResource Research Center (BRC) is a unique repository in the world, as it collects and distributes bioresources of three different levels, i.e., genetic materials (genomic and cDNA clones) and cell lines of human and animal origins as well mouse strains. With this unique feature, RIKEN BRC hopes to contribute to the comprehensive research and development on COVID-19. The research and developments have been focusing on the following four subjects: 1) SARS-CoV-2 infection and proliferation, 2) Pathogenesis and host defense, 3) Disease progression to clinically severe cases and 4) Development of effective therapies of COVID-19 patients and preventive vaccines against SARS-CoV-2 infection.

Lists of mouse strains and DNA clones useful for COVID-19 R&D from RIKEN BRC are available from following links:

Mouse resources for COVID-19 research. (Experimental Animal Division）

Human genes for COVID-19 research. (Gene Engineering Division）

---

2）Deposited cell lines

Reference	BRC Resource	Comment
Potent mouse monoclonal antibodies that block SARS-CoV-2 infection	RCB5391 R52_Spike	This cell line is a hybridoma producing anti-SARS-CoV-2 Spike antibody (Clone R52).
	RCB5392 S1D7_Spike	This cell line is a hybridoma producing anti-SARS-CoV-2 Spike antibody (Clone S1D7).
	RCB5393 S3D8_Spike	This cell line is a hybridoma producing anti-SARS-CoV-2 Spike antibody (Clone S3D8).

---

3） Papers regarding COVID-19 research in which the cell lines we have provided were used.

	BRC Resource		Reference
1	RCB2202 293T	Proc Natl Acad Sci U S A. 2008 Jun 3;105(22):7809-14	Modulation of TNF-α-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-α production and facilitates viral entry
2	RCB0995 MDCK	Clin Infect Dis. 2020 Oct 3;ciaa1517	Survival of SARS-CoV-2 and influenza virus on the human skin: Importance of hand hygiene in COVID-19
3	RCB0535 RAW 264	Viruses. 2020 Jun 28;12(7):699	Saxifraga spinulosa-Derived Components Rapidly Inactivate Multiple Viruses Including SARS-CoV-2
4	RCB0988 CACO-2 CSII-CMV-MCS-IRES2-Bsd	PLoS Pathog. 2021 Jan 21;17(1):e1009233.	SARS-CoV-2 variants with mutations at the S1/S2 cleavage site are generated in vitro during propagation in TMPRSS2-deficient cells
5	RCB0485 LA-N-5	Sci Rep. 2021 Feb 9;11(1):3379	Histone deacetylase inhibitors suppress ACE2 and ABO simultaneously, suggesting a preventive potential against COVID-19
6	RCB2202 293T	Cell. 2021 Jun 24;184(13):3452-3466.e18	An infectivity-enhancing site on the SARS-CoV-2 spike protein is targeted by COVID-19 patient antibodies
7	RCB1902 HSC-4	J Anat. 2021 Jun;238(6):1341-1354	Expression of SARS‐CoV‐2 entry factors in human oral tissue
8	RCB0209 SP2/0-Ag14	J Biol Chem. Jan-Jun 2021;296:100346	Potent mouse monoclonal antibodies that block SARS-CoV-2 infection
9	RCB0988 CACO-2 RCB2202 293T	Sci Rep. 2021 Mar 8;11(1):5376	MRC5 cells engineered to express ACE2 serve as a model system for the discovery of antivirals targeting SARS-CoV-2
10	RCB0098 A549	bioRxiv. June 30, 2021.	Host cellular RNA helicases regulate SARS-CoV-2 infection
11	RCB0211 MRC-5	Cell Rep Med. 2021 Jun 15;2(6):100311	Highly specific monoclonal antibodies and epitope identification against SARS-CoV-2 nucleocapsid protein for antigen detection tests
12	RCB2202 293T	bioRxiv. August 23, 2021	The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccines
13	RCB0098 A549	Biochemical and Biophysical Research Communications.77, 5 November 2021, Pages 146-151	Air-liquid interphase culture confers SARS-CoV-2 susceptibility to A549 alveolar epithelial cells
14	HPS0002 253G1	J Toxicol Sci . 2021;46(9):425-435	Development of alveolar and airway cells from human iPS cells: toward SARS-CoV-2 research and drug toxicity testing

---

4） Papers regarding COVID-19 research in which the cell lines we can provide were used.

	BRC Cell Line	Cell Line	Reference
1	Vero E6 RCB0988 CACO-2 Calu-3 RCB2202 293T RCB1366 HuH-7	Vero E6 Caco-2 Calu-3 HEK293T Huh7	In Vitro and Animal Models for SARS-CoV-2 research
2	Vero E6 RCB1366 HuH-7 RCB2202 293T RCB0098 A549, RCB3677 A549 EFKB3	Vero E6 Vero HUH 7.0 293T A549 EFKB3	Severe Acute Respiratory Syndrome Coronavirus 2 from Patient with Coronavirus Disease, United States
3	Vero RCB0007 HeLa, RCB3680 HeLa RCB2202 293T RCB1366 HuH-7	Vero HeLa HEK293T/F Huh7	A Thermostable mRNA Vaccine against COVID-19
4	RCB1637 293 RCB2202 293T RCB0098 A549, RCB3677 A549 RCB0218 MRC-5, known PDL Vero E6 Vero 81 RCB0007 HeLa, RCB3680 HeLa RCB1366 HuH-7	293 293T A549 MRC5 Vero E6 Vero 81 HeLa Huh7	Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV
5	RCB1648 Hep G2 RCB1366 HuH-7 RCB2202 293T Vero CHO RCB0995 MDCK	HepG2 Huh-7 293T Vero CHO MDCK	Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2
6	Vero E6 RCB1366 HuH-7	Vero E6 Huh-7	Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-κB signaling pathway
7	Vero E6 RCB1366 HuH-7	Vero E6 Huh-7	Phillyrin (KD-1) exerts anti-viral and anti-inflammatory activities against novel coronavirus (SARS-CoV-2) and human coronavirus 229E (HCoV-229E) by suppressing the nuclear factor kappa B (NF-κB) signaling pathway
8	Vero E6 RCB1366 HuH-7	Vero E6 Huh-7	Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2)
9	Vero E6 RCB1366 HuH-7	Vero E6 Huh-7	A pneumonia outbreak associated with a new coronavirus of probable bat origin
10	RCB1637 293 RCB1366 HuH-7 RCB1423 BHK-21 Vero E6	HEK293 Huh-7 BHK21 Vero-E6	Middle East Respiratory Syndrome Coronavirus ORF8b Accessory Protein Suppresses Type I IFN Expression by Impeding HSP70-Dependent Activation of IRF3 Kinase IKKε
11	RCB0007 HeLa, RCB3680 HeLa RCB2202 293T RCB1423 BHK-21 RCB0988 CACO-2	HeLa 293T BHK-21 Caco-2	COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release Syndrome
12	RCB0988 CACO-2	Caco-2	Proteomics of SARS-CoV-2-infected host cells reveals therapy targets
13	RCB0988 CACO-2	Caco-2	A metabolic handbook for the COVID-19 pandemic
14	RCB2202 293T RCB0098 A549, RCB3677 A549 BHK RCB0988 CACO-2 RCB1366 HuH-7 PK-15	293T A549 BHK Caco-2 Huh-7.5 PK-15	Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses
15	RCB2202 293T RCB0098 A549, RCB3677 A549	HEK293T A549	Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza
16	RCB2202 293T RCB0007 HeLa, RCB3680 HeLa Calu-3 RCB0218 MRC-5, known PDL	HEK293T HeLa Calu-3 MRC-5	Cell entry mechanisms of SARS-CoV-2
17	RCB2202 293T HEK293F RCB0007 HeLa, RCB3680 HeLa RCB0218 MRC-5, known PDL	HEK293T HEK293F HeLa MRC5	Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry
18	RCB1366 HuH-7 Huh-7.5	Huh-7 Huh-7.5	Influences of cyclosporin A and non-immunosuppressive derivatives on cellular cyclophilins and viral nucleocapsid protein during human coronavirus 229E replication
19	MA104 RCB1637 293	MA104 HEK293	TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes
20	RCB0218 MRC-5, known PDL	MRC-5	Natural Bis-Benzylisoquinoline Alkaloids-Tetrandrine, Fangchinoline, and Cepharanthine, Inhibit Human Coronavirus OC43 Infection of MRC-5 Human Lung Cells
21	Fcwf-4 A72 RCB0995 MDCK DH82	Fcwf-4 A72 MDCK DH82	Establishment of a Virulent Full-Length cDNA Clone for Type I Feline Coronavirus Strain C3663
22	GES-1 RCB1189 THP-1,RCB3686 THP-1	GES-1 THP-1	Glucocorticoids improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels